Table 3 Final disease activity parameters achieved in different ILAR categories during one year etanercept treatment
JIA subtype | ACR Pedi, % | Inactive disease, % | |||
|---|---|---|---|---|---|
ACR Pedi 30 | ACR Pedi 50 | ACR Pedi 70 | ACR Pedi 90 | ||
All patients (n = 197) | 90,9 | 89,8 | 85,3 | 68,5 | 67 |
Persistent oligoarticular (n = 84) | 90,5 | 90,5 | 88,1 | 77,4 | 86,9 |
Extended oligoarticular (n = 23) | 95,7 | 95,7 | 95,7 | 73,9 | 65,2 |
Polyarticular RF negative (n = 64) | 90,6 | 87,5 | 85,4 | 57,8 | 45,3 |
Polyarticular RF positive (n = 1) | 100 | 100 | 0 | 0 | 0 |
Psoriatic (n = 1) | 100 | 100 | 100 | 100 | 100 |
Enthesitis-related (n = 24) | 87,5 | 87,5 | 83,3 | 62,5 | 58,3 |